-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Qx3wfSuxCzvC3GtESc3sjhxmPq+l72T+aS70A1dreXR1KQO/BqIAqfiGnr5/n1/u
 D/1B8OU6zZPPzvdUtB672g==

<SEC-DOCUMENT>0001181431-08-067242.txt : 20081212
<SEC-HEADER>0001181431-08-067242.hdr.sgml : 20081212
<ACCEPTANCE-DATETIME>20081212192525
ACCESSION NUMBER:		0001181431-08-067242
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20081211
FILED AS OF DATE:		20081212
DATE AS OF CHANGE:		20081212

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nile Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001133869
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		115 SANSOME STREET, SUITE 310
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94104
		BUSINESS PHONE:		(415) 875-7880

	MAIL ADDRESS:	
		STREET 1:		115 SANSOME STREET, SUITE 310
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SMI PRODUCTS INC
		DATE OF NAME CHANGE:	20010206

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Kazam Joshua A
		CENTRAL INDEX KEY:			0001221355

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34058
		FILM NUMBER:		081247996

	BUSINESS ADDRESS:	
		STREET 1:		787 7TH AVE
		STREET 2:		48TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		2125544284

	MAIL ADDRESS:	
		STREET 1:		787 7TH AVE
		STREET 2:		48TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER NAME:	
		FORMER CONFORMED NAME:	KAZAM JOSHUA A
		DATE OF NAME CHANGE:	20070920

	FORMER NAME:	
		FORMER CONFORMED NAME:	KAZAM JOSHOA A
		DATE OF NAME CHANGE:	20030303
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>rrd226304.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2008-12-11</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001133869</issuerCik>
        <issuerName>Nile Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>NLTX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001221355</rptOwnerCik>
            <rptOwnerName>Kazam Joshua A</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O TWO RIVER GROUP HOLDINGS, LLC</rptOwnerStreet1>
            <rptOwnerStreet2>689 FIFTH AVENUE, 12TH FLOOR</rptOwnerStreet2>
            <rptOwnerCity>NEW YORK</rptOwnerCity>
            <rptOwnerState>NY</rptOwnerState>
            <rptOwnerZipCode>10022</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2008-12-11</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>4100</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.8236</value>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1070390</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2008-12-12</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>4100</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>1.4408</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1074490</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>613841</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Kazam Family Trust</value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>165530</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Spouse</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">This transaction was executed in multiple trades in prices ranging from $0.59 to $1.23. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a stockholder of the Issuer information regarding the number of shares and prices at which the transaction was effected.</footnote>
        <footnote id="F2">This transaction was executed in multiple trades in prices ranging from $1.25 to $1.55. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a stockholder of the Issuer information regarding the number of shares and prices at which the transaction was effected.</footnote>
        <footnote id="F3">Held by the Reporting Person's spouse as custodian for the benefit of their minor child under the Uniform Gift to Minors Act. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or any other purpose.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Daron Evans, Attorney-in-Fact for Joshua A. Kazam</signatureName>
        <signatureDate>2008-12-12</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.
<SEQUENCE>2
<FILENAME>rrd202661_228458.htm
<TEXT>
<HTML>
<HEAD>
<TITLE>
rrd202661_228458.html
</TITLE>
</HEAD>
<BODY>
<PRE>
                                POWER OF ATTORNEY

        Know all by these presents, that the undersigned hereby authorizes Peter
M. Strumph, Daron Evans, and David M. Tanen of Nile Therapeutics, Inc. ("Nile"),
to execute for and on behalf of the undersigned,  in the undersigned's  capacity
as a Section 16 reporting person of Nile,  Forms 3,  4 and 5, and any amendments
thereto,  and cause such form(s) to be filed with the United  States  Securities
and Exchange  Commission  and The NASDAQ Stock Market.  The  undersigned  hereby
grants to each such  attorney-in-fact full power and authority to do and perform
any and every act and thing  whatsoever  requisite,  necessary,  or proper to be
done in the exercise of any of the rights and powers herein granted, as fully to
all  intents  and  purposes  as the  undersigned  might or  could do  personally
present,  with full power of  substitution or revocation,  hereby  ratifying and
confirming  all that  each  such  attorney-in-fact,  or such  attorney's-in-fact
substitute or  substitutes,  shall  lawfully do or cause to be done by virtue of
this power of attorney and the rights and powers herein granted. The undersigned
acknowledges that the foregoing  attorneys-in-fact,  in serving in such capacity
at the request of the undersigned,  are not assuming,  nor is Nile assuming, any
of  the  undersigned's   responsibilities  to  comply  with  Section 16  of  the
Securities Exchange Act of 1934, as amended or the rules promulgated thereunder.

        This Power of Attorney  shall  remain in full force and effect until the
undersigned  is no longer  required to file Forms 3, 4 and 5 with respect to the
undersigned's  holdings  of, and  transactions  in,  securities  issued by Nile,
unless earlier revoked by the  undersigned in a signed writing  delivered to the
foregoing attorneys-in-fact.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 29th day of May, 2008.

                                          /s/ Joshua A. Kazam
                                          --------------------------------------
                                              Joshua A. Kazam

</PRE>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
